On January 3, 2024, Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. (collectively, “Alexion”) filed a BPCIA litigation in the District of Delaware (Case No. 1-24-cv-00005 (D. Del.)) against Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) alleging infringement of six patents, U.S. Patent Nos. 9,732,149; 9,718,880; 9,725,504; 10,590,189; 10,703,809; and 9,447,176, all of which, except for U.S. Patent No. 9,447,176, were already subject to IPR Petitions filed by Samsung Bioepis, which have been instituted for trials.  See EYLEA® (aflibercept) and Soliris® (eculizumab) IPR and BPCIA Litigation Updates. The asserted patents include four claiming methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria, one claiming pharmaceutical compositions, and one claiming an antibody.

This is the first BPCIA litigation related to a Soliris® (eculizumab) biosimilar. Samsung Bioepis’s proposed Soliris® biosimilar is called SB12, and according to Alexion’s Complaint, Samsung Bioepis’s aBLA was accepted for review by the FDA on or before July 7, 2023. The review is still pending.

This is the first public announcement of an aBLA filing for a Soliris® biosimilar. Samsung Bioepis provided its 180-day Notice of Commercial Marketing to Alexion on July 7, 2023, and thus far has declined to provide its aBLA or otherwise participate in the “patent dance.”

Soliris®’s U.S. and E.U. sales were reported to be approximately $3.2 billion USD in 2022.

We continue to monitor this case closely and will provide updates once available.

For more information about this and other biosimilar patent disputes, please visit BiologicsHQ.



The authors would like to thank April Breyer Menon for her contributions to this article.


    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website ( Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website ( Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.


    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates